TRAXNasdaqPharmaceutical PreparationsFiscal year ends December 31
First Tracks Biotherapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$36.28+1.82 (+5.28%)
Close on Oct 19, 2026
- Market cap
- $1.27B
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 12, 2026 | After market close | – | $-0.95 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 14, 2026 | After market close | – | – | – |
Press releases
Announcements First Tracks Biotherapeutics filed with the SEC
First Tracks Biotherapeutics Announces $200 Million Private Placement
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
First Tracks Biotherapeutics Announces Positive Top-Line Results for ANB033 in
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
First Tracks Biotherapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
First Tracks Biotherapeutics Announces First Quarter 2026 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
First Tracks Biotherapeutics Debuts on Nasdaq to Advance
Material agreement · Acquisition or disposition completed · Unregistered share sale · Executive or director change · Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
Dear Anaptys and future First Tracks Bio shareholders,
Regulation FD disclosure · EX-99.1 to Form 8-K